French pharmaceutical company recent years has said it will shed 466 jobs in France and Germany as part of the continuing restructure of its R&D group, and focus on immuno-oncology treatments, antibody engineering and gene therapies. In a statement, the company said the moves would allow it to "maximise the productivity of our research engine". recent years has reduced its reliance on partners such as Alnylam and Regeneron in Sanofi and shuttered R&D projects outside oncology, immunology, rare diseases and vaccines.
French pharmaceutical company Sanofi has said it will shed 466 jobs in France and Germany as part of the continuing restructure of its R&D group, and focus on immuno-oncology treatments, antibody engineering and gene therapies. In a statement, the company said the moves would allow it to "maximise the productivity of our research engine". Sanofi has reduced its reliance on partners such as Alnylam and Regeneron in recent years and shuttered R&D projects outside oncology, immunology, rare diseases and vaccines.